Valuation: Center Laboratories, Inc.

Market Cap 23.65B 725M 647M 597M 543M 1.02B 68.7B 1.03B 7.19B 2.83B 35.99B 2.72B 2.66B 114B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 27.69B 849M 758M 699M 635M 1.19B 80.43B 1.21B 8.42B 3.32B 42.14B 3.19B 3.12B 133B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
72.61%
Yield 2024
1.71%
Yield 2025 4.2%
08-11 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-21 GenEditBio Limited announced that it has received TWD 550 million in funding from Center Laboratories, Inc. CI
05-13 Center Laboratories says Jan-Mar net profit at T$1.97 bln RE
05-13 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-14 Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026 CI
03-31 WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders. CI
03-03 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-14 WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion. CI
11-11 Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
13/08/25 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/06/25 Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025. CI
09/06/25 Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million. CI
11/05/25 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 week-3.55%
Current month-4.32%
1 month-2.76%
3 months-17.50%
6 months-20.63%
Current year-24.54%
1 week 29.85
Extreme 29.85
31.2
1 month 29.85
Extreme 29.85
31.6
Current year 29.35
Extreme 29.35
48.96
1 year 29.35
Extreme 29.35
48.96
3 years 27.74
Extreme 27.739294
54.03
5 years 27.74
Extreme 27.739294
56
10 years 19.99
Extreme 19.990785
61.16
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Director of Finance/CFO - 01/08/2000
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.55%-9.66%-26.95% 729M
+2.97%+4.86%+61.54%+127.59% 1,133B
+4.33%+6.34%+39.59%+77.90% 621B
-0.03%+0.44%+24.48%+96.68% 503B
+0.03%+3.27%+39.79%+65.06% 379B
-0.57%+2.13%+69.25%+43.47% 370B
+1.58%+2.37%+22.91%+52.52% 292B
+2.90%+2.22%+3.51%+28.51% 262B
+2.36%+3.45%+51.71%+64.44% 237B
+2.26%-0.31%+29.16%+102.26% 190B
Average +1.54%+2.54%+33.23%+63.15% 398.87B
Weighted average by Cap. +1.98%+3.73%+43.30%+85.21%

Financials

2024 2025
Net sales 1.62B 49.61M 44.28M 40.85M 37.11M 69.63M 4.7B 70.7M 492M 194M 2.46B 186M 182M 7.8B 1.52B 46.49M 41.5M 38.28M 34.78M 65.25M 4.4B 66.25M 461M 182M 2.31B 175M 171M 7.31B
Net income -1.1B -33.84M -30.21M -27.87M -25.32M -47.5M -3.21B -48.23M -336M -132M -1.68B -127M -124M -5.32B 9.32B 286M 255M 235M 214M 401M 27.08B 407M 2.84B 1.12B 14.19B 1.07B 1.05B 44.94B
Net Debt 4.48B 137M 123M 113M 103M 193M 13.01B 196M 1.36B 537M 6.82B 516M 505M 21.6B 4.04B 124M 111M 102M 92.71M 174M 11.74B 177M 1.23B 484M 6.15B 465M 455M 19.48B
Projected Income Statement - Annual - Center Laboratories, Inc.
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
22/10/26 NT$29.90 0.00% 798,762
21/10/26 NT$29.90 0.00% 590,553
20/10/26 NT$29.90 -0.50% 586,110
19/10/26 NT$30.05 -3.06% 1,406,660
16/10/26 NT$31.00 +0.16% 759,987
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock